Form 8-K - Current report:
SEC Accession No. 0001641172-25-026110
Filing Date
2025-09-02
Accepted
2025-09-02 06:02:27
Documents
17
Period of Report
2025-09-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 47786
2 EX-10.1 ex10-1.htm EX-10.1 104265
3 EX-10.2 ex10-2.htm EX-10.2 104259
4 EX-10.3 ex10-3.htm EX-10.3 104253
5 GRAPHIC form8-k_001.jpg GRAPHIC 7657
  Complete submission text file 0001641172-25-026110.txt   655658

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cycc-20250901.xsd EX-101.SCH 3743
7 XBRL DEFINITION FILE cycc-20250901_def.xml EX-101.DEF 26581
8 XBRL LABEL FILE cycc-20250901_lab.xml EX-101.LAB 36613
9 XBRL PRESENTATION FILE cycc-20250901_pre.xml EX-101.PRE 25205
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5747
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 251282779
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)